Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) Shares Outstanding (Diluted Average) (2023 - 2025)

Kura Oncology (KURA) has disclosed Shares Outstanding (Diluted Average) for 3 consecutive years, with $87.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 1.76% to $87.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $87.7 million, a 1.76% increase, with the full-year FY2025 number at $87.7 million, up 1.76% from a year prior.
  • Shares Outstanding (Diluted Average) was $87.7 million for Q4 2025 at Kura Oncology, roughly flat from $87.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $87.7 million in Q4 2025 to a low of $68.4 million in Q1 2023.
  • A 3-year average of $81.3 million and a median of $85.7 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 23.4% in 2024, then increased 0.8% in 2025.
  • Kura Oncology's Shares Outstanding (Diluted Average) stood at $73.2 million in 2023, then rose by 17.66% to $86.2 million in 2024, then increased by 1.76% to $87.7 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Shares Outstanding (Diluted Average) are $87.7 million (Q4 2025), $87.6 million (Q3 2025), and $87.5 million (Q2 2025).